ADT Therapy for Prostate: Counseling Needed
If the man in your life has been prescribed androgen deprivation therapy (ADT) as part of the treatment for prostate cancer, you’re both best off if you’re warned ahead of time about possible side-effects and offered advice about coping strategies. Although research done at the University of California-San Francisco and published in the Journal of Urology in 2014 showed that there was “no meaningful decline in emotional quality of life two years after treatment,” the study also underscored the fact that patients are “likely to experience more adverse side-effects and complications from the treatment than from the cancer itself”. These unwelcome symptoms can include hot flashes, decreased libido, fatigue, decreased bone and muscle mass, increased total body fat content, and even possible harmful cardiovascular effects.
A release from the publisher notes that previous studies have reported cognitive and affective symptoms following ADT, particularly in the elderly, including emotional upset (tearfulness, irritability, and anger), decreased motivation, hopelessness, and cognitive interruptions in attention, memory, and visual processing. Some studies have linked ADT use to depression, although it is not clear whether such effects are a direct consequence of ADT itself or perhaps associated with age, comorbidities, hot flashes, fatigue, and insomnia. The UC-San Francisco team recommends counseling about the potential adverse effects of ADT as well as the interventions to improve mental and emotional health such as exercise programs and diet.
ADT, which suppresses the production of testosterone by either with medication or surgery, remains the gold standard for treating advanced prostate cancer, either alone or with radiation therapy. Benefits include reduction of tumor burden, delayed cancer progression, and overall improvement in survival in some cases. The current authors evaluated the effects of ADT on mental and emotional well-being in men diagnosed with localized prostate cancer using data from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry, which consists of data from largely community-based practices across the United States. Over 3,000 men completed a pretreatment and at least one posttreatment quality of life assessment checklist.
The authors focused on men newly diagnosed with localized (non-metastatic) prostate cancer in 1995-2011 and treated with radical prostatectomy, brachytherapy, radiation therapy, or primary androgen deprivation therapy (PADT). Of men included in the study 75% were treated with local therapy, 20% combination treatment, and five percent PADT. Among men in the PADT group, 84% were treated with luteinizing hormone-releasing hormone agonist monotherapy and 16% received combined androgen blockade.